Search

everythinglearnresearchcommunity

for

Search:↓

The effectiveness of Dutasteride compared to Finasteride in treating hair loss, with evidence given such as studies and experiences, as well as discussion around whether one should switch from Finasteride to Dutasteride. There is also a discussion on post-Dutasteride syndrome.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

Dutasteride and finasteride have similar risk profiles despite Dutasteride blocking more types of 5AR in the brain. Some users report no mood issues with either drug, and it is suggested that Dutasteride's larger molecular size may limit its ability to cross the blood-brain barrier.

Topical dutasteride may be effective for hair loss by staying in the scalp and minimizing bloodstream absorption, potentially improving hair results and reducing side effects. The user seeks advice on its effectiveness.

The conversation is about skepticism regarding new hair loss treatments until they are FDA approved. People have been joking about treatments being 5-7 years away for decades.

Dutasteride mesotherapy showed increased hair density and diameter without reducing serum DHT levels in a small study. However, the sample size was too small to make definitive claims about its efficacy.

The potential effectiveness of topical dutasteride, as well as other hair loss treatments such as finasteride, RU58841, minoxidil, and various vitamins. Experiences from users who have used these treatments were shared.

Peppermint oil at 3% was found to improve hair growth more effectively than Minoxidil. The user is also using a topical caffeine hair growth oil and making their own peppermint solution to combat hair thinning.

The post and conversation are about a user's 6-month progress using topical dutasteride, 8% minoxidil, tretinoin, 2% ketoconazole shampoo, microneedling, oral finasteride, pumpkin seed oil, Vitamin D3, a men's multivitamin, rosemary oil, and 5% minoxidil foam for hair loss treatment.

The availability of Topical Dutasteride, a potential treatment for hair loss, which can be purchased without prescription from MinoxidilMax. Other treatments discussed include Topical Finasteride and PRP injections, with discussion around dosage, efficacy, side-effects and safety.

The user is using finasteride, minoxidil, topical treatments, and supplements for hair loss but is losing progress and considering switching to dutasteride. They seek success stories to boost morale.

Peptides like TB500, KPV, GHK-CU, and BPC-157 are overhyped for hair growth with limited proven effectiveness in humans. Combining peptides with delivery methods like iontophoresis and sonophoresis shows promise, but many claims remain unproven.

The conversation discusses the potential of long-chain unsaturated fatty acids, like oleic and linoleic acid, as an additional treatment for hair loss, which may inhibit the enzyme responsible for converting testosterone to DHT and promote hair growth. Users humorously suggest using oils topically and discuss other hair loss treatments, but the main focus is on the science behind fatty acids and their role in hair health.

User shares 1-year progress using topical finasteride and minoxidil for hair loss, with positive results. Some users discuss trying topical dutasteride and varying dosages, while others share their experiences and ask about specific products.

Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.

Finasteride can impact neurosteroids, potentially causing depression and other side effects in some users. Despite these concerns, many continue using it for hair loss, with some switching to topical applications to mitigate side effects.

Testosterone within the normal range does not significantly contribute to male pattern baldness (MPB); DHT is the main factor that can be controlled. Genetics play a crucial role in hair loss, and treatments like finasteride and dutasteride, which block DHT, can help despite potentially raising testosterone levels.

Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.

The post discusses frustration over the limited and not always effective treatments for hair loss, mainly Minoxidil and Finasteride. The conversation includes mentions of potential new treatments like GT20029, HMI-115, CosmeRNA, KX-826, and microneedling, but also highlights the challenges of funding and prioritizing research in this area.

The user's experience taking Pyrilutamide, a drug for hair loss treatment, and their use of it in combination with other treatments such as Minoxidil, Finasteride and RU58841. They have experienced positive results so far with no major side effects.

The conversation discusses RU58841, a compound for hair loss treatment, which was found to be effective in a 6-month trial but was not pursued due to financial issues or marketability concerns, not safety. Some users are considering crowdfunding to release the research data, while others discuss personal experiences and safety concerns with RU58841.

The conversation discusses using ketoconazole, an anti-androgen, for hair loss and whether mesotherapy with dermarolling could enhance its absorption into the scalp. The user questions if the typical 2% ketoconazole shampoo dose would be effective when used after dermarolling to target androgen receptors in the scalp.

The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.

User Basic_Football999 discusses concerns about negative dutasteride experiences. Replies suggest dutasteride is effective, but some users may have issues with dosing frequency or genetic factors affecting results.

User shared their 14-month progress using topical Dutasteride at 0.1% for hair loss, with significant improvement and no side effects. Others discussed concerns about fertility and questioned the authenticity of the results.

New potential hair loss treatment uses molecules from hairy moles to stimulate follicle growth. Topical solution requires less frequent application, like Botox injections a few times per year.

The conversation humorously speculates on whether an elderly man's good hairline is due to finasteride, dutasteride, or genetics. It also discusses the role of DHT and genetics in hair loss.

A user is considering microneedling to enhance absorption of a prescribed topical hair loss treatment containing Minoxidil, Dutasteride, and Latanoprost, while already taking oral Minoxidil and Dutasteride. They seek advice on the effectiveness and safety of combining these treatments, especially due to the cost and their desire to maximize results.

A 43-year-old man started treatment for hair loss with finasteride, minoxidil, Qilib rebalance, and Trigain Caffeine shampoo, and is taking vitamin D supplements. He hopes to share positive results after a few months.

The conversation discusses the delay in the release of a new hair loss treatment, Pyrilutamide, and speculates on potential safety concerns as a reason for the delay. It also mentions GT20029 as another future treatment option, with a release at least five years away, and touches on the avoidance of research chemicals due to uncertainty about their authenticity.